tuneTypical Dose
1,750 mg/day in the insulin-sensitivity trial, but disease-specific protocols vary substantially
Supplement
TUDCA
Tauroursodeoxycholic acid
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Effect timing depends entirely on the disease context and endpoint. There is no general consumer effect window.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
TUDCA is a bile-acid derivative with narrow human evidence in specific liver, metabolic, and neurologic settings, not a proven general liver-support or wellness supplement.
TUDCA is marketed heavily for liver support, bile flow, metabolism, and neuroprotection. Human data do exist, but they are narrow and condition specific. The best evidence comes from small mechanistic metabolic work and disease-specific trials such as ALS or cholestatic liver disease. That does not justify broad use framing for healthy people or casual “detox liver support” claims.
TUDCA is a taurine-conjugated bile acid linked to bile-acid signaling, endoplasmic-reticulum stress biology, and cell-survival pathways. Those mechanisms are real, but the current human evidence supports only narrow clinical translation rather than broad supplement claims.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Narrow human evidence for disease-specific metabolic or neurologic effects
- No established broad liver-support benefit for healthy supplement users
Secondary Outcomes
- Human metabolic physiology signal in insulin-resistant obesity
- Preliminary ALS-specific therapeutic signal
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
- Lactation
- Clinician-unevaluated liver or biliary symptoms
Side effects
- Diarrhea
- Abdominal discomfort
- Nausea
Interactions
- Bile-acid sequestrants
- Glucose-lowering drugs
Avoid if
- You are using it as a casual liver detox supplement
- You have unexplained jaundice, persistent abdominal pain, or known biliary disease without clinician guidance
Evidence
Study-level References
tudca-SRC-001Randomized controlled trial
Sourceopen_in_newKars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899-1905. doi:10.2337/db10-0308. PMID:20522594.
Population: Obese insulin-resistant men and women.
Dose protocol: 1,750 mg/day for 4 weeks
Key findings: Improved liver and muscle insulin sensitivity in obese insulin-resistant adults.
Notes: Strongest human metabolic signal, but mechanistic and short term.
Paper content
This small mechanistic human trial showed that 4 weeks of TUDCA improved liver and skeletal-muscle insulin sensitivity in obese insulin-resistant adults, while leaving adipose tissue insulin sensitivity unchanged. The study supports a biologic metabolic signal for TUDCA, but it was short, intensive, and not a practical supplement-outcomes trial for weight loss, diabetes prevention, or general wellness use.
tudca-SRC-002Randomized controlled trial
Sourceopen_in_newElia AE, Lalli S, Monsurrò MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45-52. doi:10.1111/ene.12664. PMID:25664595.
Population: Adults with amyotrophic lateral sclerosis receiving riluzole.
Dose protocol: 1 g twice daily as add-on therapy in ALS
Key findings: Slowed functional decline in a small ALS trial.
Notes: Disease-specific result that should not be generalized.
Paper content
This small pilot ALS study found that add-on TUDCA slowed functional decline and increased responder rates compared with placebo in patients already receiving riluzole. The result is clinically interesting, but the sample was small and disease specific. It does not support broad neuroprotection or general supplement claims outside the ALS context.
tudca-SRC-003Controlled clinical trial
Sourceopen_in_newFerri F, Bernocchi P, Fedeli S. Taurodeoxycholic acid in the treatment of primary biliary cirrhosis. A controlled study in comparison to ursodeoxycholic acid. Clin Ter. 1993;143(4):321-326. PMID:8258267.
Population: Adults with primary biliary cirrhosis.
Dose protocol: 12 to 15 mg/kg/day in primary biliary cirrhosis
Key findings: Did not outperform UDCA and appeared less well tolerated in an older comparator trial.
Notes: Useful for keeping liver-support claims grounded.
Paper content
This older controlled trial is useful mainly because it keeps TUDCA claims grounded. In primary biliary cirrhosis, TUDCA did not clearly outperform the established bile acid ursodeoxycholic acid and appeared less well tolerated. That supports viewing TUDCA as a condition-specific bile acid with mixed clinical value, not as an obviously superior liver-support compound.
tudca-SRC-004Double-blind, placebo-controlled randomized trial.
Sourceopen_in_newLadakis DC, Harrison KL, Smith MD, et al. Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med. 2025;6(3):100522. doi:10.1016/j.medj.2024.09.011. PMID:39447576.
Population: Adults with progressive multiple sclerosis.
Dose protocol: TUDCA 2 g/day for 16 weeks.
Key findings: TUDCA was safe and well tolerated in progressive MS patients. Bile acid metabolite profiles predicted disease progression.
Notes: Modern double-blind placebo-controlled RCT. Primary safety focus with biomarker exploration. Extends TUDCA evidence into neuroinflammatory disease.
Paper content
This double-blind, placebo-controlled RCT tested TUDCA at 2 g/day for 16 weeks in 47 participants with progressive multiple sclerosis. The primary focus was safety, tolerability, and bile acid metabolite profiling. TUDCA supplementation was safe and well tolerated. The study also found that specific bile acid metabolite profiles predicted MS disease progression. This is one of the few modern human RCTs of TUDCA and extends the evidence base into neuroinflammatory disease beyond the earlier ALS trials. The safety data are particularly valuable for informing the TUDCA supplementation conversation.